ArticleJournal of statistical theory and applications : JSTA2026
Improved Estimation of Rates of Glaucoma Progression Using Spatial Two-Fold Linear Mixed Models.
Article in Journal of statistical theory and applications : JSTA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visual field testing is essential for detecting glaucomatous damage. Traditional approaches such as pointwise linear regression often fail to account for the spatial correlations and hierarchical structure among test locations. We propose a two-fold linear mixed model that incorporates both eye-level and within-eye cluster-level random effects. Using the Bascom Palmer Glaucoma Repository, we show that our model outperforms conventional pointwise linear regression and permutation-based pointwise regression. In simulation studies, the proposed method yields markedly lower mean squared error than ordinary least squares, achieving MSEs of 0.41 (lower eye) and 0.50 (upper eye), compared with 1.12 and 1.72, respectively, while also reducing false-positive and false-negative rates. This framework provides improved precision and interpretability for quantifying visual field progression in glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.